- Home
- JELD vs TLSA Comparison
JELD vs TLSA Comparison
Compare JELD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | TLSA |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4M | 192.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JELD | TLSA |
|---|---|---|
| Price | $2.47 | $1.39 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $3.94 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 234.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $0.73 |
| 52 Week High | $8.38 | $2.60 |
Technical Indicators
Market Signals| Indicator | JELD | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 44.53 |
| Support Level | $2.00 | $1.33 |
| Resistance Level | $3.10 | $1.44 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 43.84 | 35.62 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.